Literature DB >> 10887156

Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2.

M Giovannini1, E Robanus-Maandag, M van der Valk, M Niwa-Kawakita, V Abramowski, L Goutebroze, J M Woodruff, A Berns, G Thomas.   

Abstract

Hemizygosity for the NF2 gene in humans causes a syndromic susceptibility to schwannoma development. However, Nf2 hemizygous mice do not develop schwannomas but mainly osteosarcomas. In the tumors of both species, the second Nf2 allele is inactivated. We report that conditional homozygous Nf2 knockout mice with Cre-mediated excision of Nf2 exon 2 in Schwann cells showed characteristics of neurofibromatosis type 2. These included schwannomas, Schwann cell hyperplasia, cataract, and osseous metaplasia. Thus, the tumor suppressor function of Nf2, here revealed in murine Schwann cells, was concealed in hemizygous Nf2 mice because of insufficient rate of second allele inactivation in this cell compartment. The finding of this conserved function documents the relevance of the present approach to model the human disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10887156      PMCID: PMC316733     

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  36 in total

Review 1.  Schwann cell differentiation.

Authors:  T S Zorick; G Lemke
Journal:  Curr Opin Cell Biol       Date:  1996-12       Impact factor: 8.382

2.  Protamine-Cre recombinase transgenes efficiently recombine target sequences in the male germ line of mice, but not in embryonic stem cells.

Authors:  S O'Gorman; N A Dagenais; M Qian; Y Marchuk
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-23       Impact factor: 11.205

Review 3.  Tumor suppressor gene mutations in mice.

Authors:  T Jacks
Journal:  Annu Rev Genet       Date:  1996       Impact factor: 16.830

4.  Detection of cellular proteins that interact with the NF2 tumor suppressor gene product.

Authors:  H Takeshima; I Izawa; P S Lee; N Safdar; V A Levin; H Saya
Journal:  Oncogene       Date:  1994-08       Impact factor: 9.867

5.  P0 promoter directs expression of reporter and toxin genes to Schwann cells of transgenic mice.

Authors:  A Messing; R R Behringer; J P Hammang; R D Palmiter; R L Brinster; G Lemke
Journal:  Neuron       Date:  1992-03       Impact factor: 17.173

6.  Impairment of cell adhesion by expression of the mutant neurofibromatosis type 2 (NF2) genes which lack exons in the ERM-homology domain.

Authors:  H Koga; N Araki; H Takeshima; T Nishi; T Hirota; Y Kimura; M Nakao; H Saya
Journal:  Oncogene       Date:  1998-08-20       Impact factor: 9.867

7.  Peripheral nerve sheath tumors: an electron microscopic study of 43 cases.

Authors:  R A Erlandson; J M Woodruff
Journal:  Cancer       Date:  1982-01-15       Impact factor: 6.860

8.  The triple origin of skull in higher vertebrates: a study in quail-chick chimeras.

Authors:  G F Couly; P M Coltey; N M Le Douarin
Journal:  Development       Date:  1993-02       Impact factor: 6.868

9.  A gene family consisting of ezrin, radixin and moesin. Its specific localization at actin filament/plasma membrane association sites.

Authors:  N Sato; N Funayama; A Nagafuchi; S Yonemura; S Tsukita; S Tsukita
Journal:  J Cell Sci       Date:  1992-09       Impact factor: 5.285

10.  Krox-20 controls myelination in the peripheral nervous system.

Authors:  P Topilko; S Schneider-Maunoury; G Levi; A Baron-Van Evercooren; A B Chennoufi; T Seitanidou; C Babinet; P Charnay
Journal:  Nature       Date:  1994-10-27       Impact factor: 49.962

View more
  152 in total

1.  A chemical biology approach identified PI3K as a potential therapeutic target for neurofibromatosis type 2.

Authors:  Alejandra M Petrilli; Marisa A Fuse; Mathew S Donnan; Marga Bott; Nicklaus A Sparrow; Daniel Tondera; Julia Huffziger; Corina Frenzel; C Siobhan Malany; Christophe J Echeverri; Layton Smith; Cristina Fernández-Valle
Journal:  Am J Transl Res       Date:  2014-10-11       Impact factor: 4.060

Review 2.  Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms.

Authors:  Steven L Carroll
Journal:  Acta Neuropathol       Date:  2011-12-11       Impact factor: 17.088

Review 3.  Brain tumours: classification and genes.

Authors:  V P Collins
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-06       Impact factor: 10.154

Review 4.  Merlin: a tumour suppressor with functions at the cell cortex and in the nucleus.

Authors:  Wei Li; Jonathan Cooper; Matthias A Karajannis; Filippo G Giancotti
Journal:  EMBO Rep       Date:  2012-03       Impact factor: 8.807

Review 5.  Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems.

Authors:  Fausto J Rodriguez; Andrew L Folpe; Caterina Giannini; Arie Perry
Journal:  Acta Neuropathol       Date:  2012-02-12       Impact factor: 17.088

6.  The NF2 tumor suppressor, Merlin, regulates epidermal development through the establishment of a junctional polarity complex.

Authors:  Andrew B Gladden; Alan M Hebert; Eveline E Schneeberger; Andrea I McClatchey
Journal:  Dev Cell       Date:  2010-11-16       Impact factor: 12.270

7.  An Essential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis.

Authors:  Dina S Stepanova; Galina Semenova; Yin-Ming Kuo; Andrew J Andrews; Sylwia Ammoun; C Oliver Hanemann; Jonathan Chernoff
Journal:  Cancer Res       Date:  2017-07-20       Impact factor: 12.701

Review 8.  Harnessing preclinical mouse models to inform human clinical cancer trials.

Authors:  David H Gutmann; Kim Hunter-Schaedle; Kevin M Shannon
Journal:  J Clin Invest       Date:  2006-04       Impact factor: 14.808

9.  The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression.

Authors:  Guang-Hui Xiao; Ryan Gallagher; Justin Shetler; Kristine Skele; Deborah A Altomare; Richard G Pestell; Suresh Jhanwar; Joseph R Testa
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

Review 10.  Neurofibromatosis-related tumors: emerging biology and therapies.

Authors:  Matthias A Karajannis; Rosalie E Ferner
Journal:  Curr Opin Pediatr       Date:  2015-02       Impact factor: 2.856

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.